Cell line · CVCL_2574
Papers30
1 to 20 of 30
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| High TMEM161A expression drives malignant phenotypes and predicts poor prognosis in colorectal cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39605519 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Regulation of GTPase function by autophosphorylation. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. | J Exp Clin Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. | Cancers (Basel) | 2020 | Its Methods give the RRID and name the line | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. | Cell Rep | 2017 | Cellosaurus cites it | PubMed | |
| Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. | Clin Cancer Res | 2015 | Cellosaurus cites it | PubMed | |
| The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. | Nat Commun | 2015 | Cellosaurus cites it | PubMed | |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. | Clin Cancer Res | 2015 | Cellosaurus cites it | PubMed | |
| Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. | Cancer Res | 2014 | Cellosaurus cites it | PubMed | |
Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and α-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. | J Proteome Res | 2014 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2574/papers